Edgewise Therapeutics (EWTX) Other financing activities (2020 - 2026)

Edgewise Therapeutics (EWTX) has 7 years of Other financing activities data on file, last reported at $12.2 million in Q1 2026.

• For the quarter ending Q1 2026, Other financing activities rose 438.39% year-over-year to $12.2 million; the trailing twelve-month figure through Mar 2026 stood at $17.7 million (up 1348.49% YoY), and the FY2025 full-year result was $7.8 million, up 778.72% from the prior year.
• Other financing activities grew to $12.2 million in Q1 2026, from $3.6 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $12.2 million in Q1 2026 to a low of -$3.1 million in Q3 2024.
• A 5-year average of $1.3 million and a median of $73000.0 in 2022 frame the typical range for Other financing activities.
• Peak annual rise in Other financing activities reached 9071.43% in 2024, while the deepest fall reached 102766.67% in 2024.
• Tracing EWTX's Other financing activities over 5 years: stood at -$60000.0 in 2022, then jumped by 203.33% to $62000.0 in 2023, then jumped by 650.0% to $465000.0 in 2024, then jumped by 684.95% to $3.6 million in 2025, then surged by 233.51% to $12.2 million in 2026.
• Business Quant data shows EWTX's Other financing activities at $12.2 million in Q1 2026, $3.6 million in Q4 2025, and $3.6 million in Q3 2025.